Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed Cancers

 Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed Cancers

Navrogen and Levena Collaborate to Develop ADCs for Humoral Immuno-Suppressed Cancers

Shots:

  • Navrogen expands its collaboration with Levena to develop ADCs targeting humoral immuno-suppressed cancers
  • The collaboration will deploy Levena’s linker and cytotoxic payload chemistry expertise with Navrogen’s cancer-targeting Abs discovered utilizing HIO platform technologies. Levena will also utilize its process development and GMP capabilities
  • The expansion of collaboration allows Navrogen to advance ADCs toward clinical studies

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post